Nyhet från partner

Rights issue takes Expres2ion breast cancer vaccine to phase I

Publicerad: 14 juni 2024, 08:45

Having validated its vaccine platform in Covid-19, Expres2ion Biotech now turns to the treatment of breast cancer.

A SEK 60 million rights issue of units will fund a phase I study with the breast cancer vaccine candidate ES2B-C001, building on promising preclinical results.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

•Denna källa har få eller inga artiklar bakom betalvägg

Läs hela texten hos Biostock

Nyhet från partner

Rights issue takes Expres2ion breast cancer vaccine to phase I

Nyhetsbrev